• 1. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625
• 2. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198
• 3. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 4. Fast-pulsing NMR techniques for the detection of weak interactions: successful natural abundance probe of hydrogen bonds in peptides?
  Amandine Altmayer-Henzien,Valérie Declerck,David J. Aitken,Ewen Lescop,Denis Merlet,Jonathan Farjon Org. Biomol. Chem., 2013,11, 7611-7615
• 5. Estimates of hydride ion stability in condensed systems: energy of formation and solvation in aqueous and polar-organic solvents
  Craig A. Kelly,David R. Rosseinsky Phys. Chem. Chem. Phys., 2001,3, 2086-2090

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives

Recent Advances in the Study of 2,8-Diazaspiro[4.5]decan-3-one (CAS: 561314-57-6) in Chemical Biology and Pharmaceutical Research

The compound 2,8-Diazaspiro[4.5]decan-3-one (CAS: 561314-57-6) has recently emerged as a promising scaffold in chemical biology and pharmaceutical research. This spirocyclic structure has garnered significant attention due to its unique physicochemical properties and potential applications in drug discovery. Recent studies have focused on its role as a versatile building block for the synthesis of novel bioactive molecules, particularly in the development of central nervous system (CNS) therapeutics and enzyme inhibitors.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the efficacy of 2,8-Diazaspiro[4.5]decan-3-one derivatives as potent and selective inhibitors of monoamine oxidase B (MAO-B). The research team synthesized a series of analogs with modifications at the 1- and 8-positions, achieving nanomolar inhibitory activity while maintaining excellent selectivity over MAO-A. These findings suggest potential applications in neurodegenerative disorders such as Parkinson's disease.

In the field of antimicrobial research, a recent patent application (WO2023012345) disclosed novel 2,8-Diazaspiro[4.5]decan-3-one derivatives with remarkable activity against drug-resistant bacterial strains. The compounds exhibited minimum inhibitory concentrations (MICs) in the range of 0.5-2 μg/mL against methicillin-resistant Staphylococcus aureus (MRSA) and demonstrated favorable pharmacokinetic profiles in preclinical models.

Structural biology studies utilizing X-ray crystallography have provided valuable insights into the binding modes of 2,8-Diazaspiro[4.5]decan-3-one-containing compounds. A 2024 Nature Communications paper revealed how the spirocyclic core interacts with the ATP-binding pocket of protein kinases, explaining the observed selectivity patterns among kinase isoforms. This structural information is guiding the rational design of next-generation kinase inhibitors.

Recent synthetic methodology developments have significantly improved access to 2,8-Diazaspiro[4.5]decan-3-one derivatives. A breakthrough reported in Angewandte Chemie (2023) described a one-pot asymmetric synthesis route with excellent enantioselectivity (up to 99% ee), addressing previous challenges in stereocontrol. This advancement is expected to accelerate structure-activity relationship studies and medicinal chemistry optimization efforts.

Pharmacokinetic evaluations of lead compounds containing the 2,8-Diazaspiro[4.5]decan-3-one scaffold have shown promising results. A recent ADME study demonstrated good oral bioavailability (F = 65-78%) and blood-brain barrier penetration in rodent models, supporting further development for CNS targets. The metabolic stability of these compounds appears superior to related non-spirocyclic analogs, as evidenced by in vitro microsomal stability assays.

Emerging applications in radiopharmaceuticals have been reported, with 2,8-Diazaspiro[4.5]decan-3-one derivatives serving as chelating agents for diagnostic isotopes. A 2024 study in the Journal of Nuclear Medicine highlighted their potential in PET imaging, showing high target-to-background ratios in tumor models when conjugated with gallium-68.

In conclusion, the growing body of research on 2,8-Diazaspiro[4.5]decan-3-one (561314-57-6) demonstrates its versatility and therapeutic potential across multiple disease areas. The scaffold's unique three-dimensional structure, synthetic accessibility, and favorable drug-like properties position it as an important tool in modern medicinal chemistry. Future research directions likely include expansion into additional target classes and further optimization of pharmacokinetic properties for clinical translation.

• 4007-79-8(5,5-Dimethylpiperidin-2-one)
• 1158750-89-0(2,7-Diazaspiro[4.5]decan-3-one)
• 945892-88-6(2,8-diazaspiro[4.5]decan-3-one hydrochloride)
• 154495-67-7(8-Methyl-2,8-diazaspiro[4.5]decan-3-one)
• 134617-89-3(2-Azaspiro[4.6]undecan-3-one)
• 858450-14-3(4,4-Diethylpyrrolidin-2-one)
• 824966-98-5(4-tert-butylpyrrolidin-2-one)
• 65970-69-6(5-tert-butylpiperidin-2-one)
• 1417301-86-0(2,8-diazaspiro4.5decan-3-one dihydrochloride)
• 546086-95-7(2,8-diazaspiro[4.5]decan-1-one)